These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 20137943)

  • 1. Discovery of
    Che J; Dai X; Gao J; Sheng H; Zhan W; Lu Y; Li D; Gao Z; Jin Z; Chen B; Luo P; Yang B; Hu Y; He Q; Weng Q; Dong X
    J Med Chem; 2021 Aug; 64(16):12163-12180. PubMed ID: 34375113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
    Heightman TD; Berdini V; Bevan L; Buck IM; Carr MG; Courtin A; Coyle JE; Day JEH; East C; Fazal L; Griffiths-Jones CM; Howard S; Kucia-Tran J; Martins V; Muench S; Munck JM; Norton D; O'Reilly M; Palmer N; Pathuri P; Peakman TM; Reader M; Rees DC; Rich SJ; Shah A; Wallis NG; Walton H; Wilsher NE; Woolford AJ; Cooke M; Cousin D; Onions S; Shannon J; Watts J; Murray CW
    J Med Chem; 2021 Aug; 64(16):12286-12303. PubMed ID: 34387469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises.
    Pervanidis KA; D'Angelo GD; Weisner J; Brandherm S; Rauh D
    J Med Chem; 2024 Apr; 67(8):6052-6063. PubMed ID: 38592948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery, Optimization, and Evaluation of Novel Pyridin-2(1
    Xu Z; Peng X; Zhang R; Ji Y; You M; Wang D; Shen Y; Zheng M; Li C; Ai J; Liu H
    J Med Chem; 2024 Jan; 67(2):1168-1183. PubMed ID: 38227770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selectivity Studies and Free Energy Calculations of AKT Inhibitors.
    Zhong HA; Goodwin DT
    Molecules; 2024 Mar; 29(6):. PubMed ID: 38542870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents.
    Kayser-Bricker KJ; Glenn MP; Lee SH; Sebti SM; Cheng JQ; Hamilton AD
    Bioorg Med Chem; 2009 Feb; 17(4):1764-71. PubMed ID: 19179081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Into Deep Water: Optimizing BCL6 Inhibitors by Growing into a Solvated Pocket.
    Lloyd MG; Huckvale R; Cheung KJ; Rodrigues MJ; Collie GW; Pierrat OA; Gatti Iou M; Carter M; Davis OA; McAndrew PC; Gunnell E; Le Bihan YV; Talbot R; Henley AT; Johnson LD; Hayes A; Bright MD; Raynaud FI; Meniconi M; Burke R; van Montfort RLM; Rossanese OW; Bellenie BR; Hoelder S
    J Med Chem; 2021 Dec; 64(23):17079-17097. PubMed ID: 34846884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1.
    Mahajan P; Wadhwa B; Barik MR; Malik F; Nargotra A
    Mol Divers; 2020 Feb; 24(1):45-60. PubMed ID: 30798436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational transition paths harbor structures useful for aiding drug discovery and understanding enzymatic mechanisms in protein kinases.
    Wong CF
    Protein Sci; 2016 Jan; 25(1):192-203. PubMed ID: 26032746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.
    Mattmann ME; Stoops SL; Lindsley CW
    Expert Opin Ther Pat; 2011 Sep; 21(9):1309-38. PubMed ID: 21635152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.
    Collins I; Caldwell J; Fonseca T; Donald A; Bavetsias V; Hunter LJ; Garrett MD; Rowlands MG; Aherne GW; Davies TG; Berdini V; Woodhead SJ; Davis D; Seavers LC; Wyatt PG; Workman P; McDonald E
    Bioorg Med Chem; 2006 Feb; 14(4):1255-73. PubMed ID: 16249095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design.
    Harris TK
    IUBMB Life; 2003 Mar; 55(3):117-26. PubMed ID: 12822887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azole-based inhibitors of AKT/PKB for the treatment of cancer.
    Zeng Q; Allen JG; Bourbeau MP; Wang X; Yao G; Tadesse S; Rider JT; Yuan CC; Hong FT; Lee MR; Zhang S; Lofgren JA; Freeman DJ; Yang S; Li C; Tominey E; Huang X; Hoffman D; Yamane HK; Fotsch C; Dominguez C; Hungate R; Zhang X
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1559-64. PubMed ID: 20137943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics.
    Zeng Q; Bourbeau MP; Wohlhieter GE; Yao G; Monenschein H; Rider JT; Lee MR; Zhang S; Lofgren J; Freeman D; Li C; Tominey E; Huang X; Hoffman D; Yamane H; Tasker AS; Dominguez C; Viswanadhan VN; Hungate R; Zhang X
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1652-6. PubMed ID: 20137932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
    Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.